+1-646-568-9980, +44-203-287-6050
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
hemophilia a treatment market

Hemophilia A Treatment Market [By Standard of Diagnosis (Mild Moderate & Severe), By Approved Drugs (Afstyla, Eloctate, Hemlibra, Kogenate FS, Kovaltry, Nuwiq & Obizur), By Care Delivery Model (Prophylaxis, On-demand therapy & Inhibitor therapy) and By Regions]: Market Estimate & Forecast, 2016 - 2022

Published: Feb 2018
Pages: 100
Format: PDF
Report ID: PM1107
License and Pricing
Buy Now Inquire Before Buying

Report Summary

The global Hemophilia A treatment market was valued at approximately USD 8 billion in 2016. The Report covers the Hemophilia A therapeutic area, prevalent population, current treatment and diagnosis patterns. The Report provides the forecast of Hemophilia A treatment market globally, by G7 countries, disease care at product level. The Report also offers an in-depth view of the Hemophilia A treatment market opportunities by focusing on major drivers facing this market. Hemophilia A, also called factor VIII (FVIII) deficiency or classic Hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a change in a gene.

Hemophilia A market accounts for the largest share in total Hemophilia treatment market due to the rising prevalence and increase in demand of prophylactic treatments. In terms of the geographic distribution, Unites States holds the dominant market position followed by top five European countries (France, Germany, Italy, Spain and the U.K.) and Japan. The major drivers of the U.S. market are rising prevalent cases of Hemophilia A, awareness of the disease, access to new treatment modalities, improved diagnosis, and increase in the usage of both prophylactic and recombinant treatment options.

North America Hemophilia A Treatment Market By Care Delivery Model, 2016 - 2022

North America Hemophilia A Treatment Market By Care Delivery Model, 2016 - 2022

Inside circle shows data for 2016 and outer circle shows data for 2022

The market for Haemophilia A treatment market looks commercially significant driven by increase rising demand for recombinant and prophylaxis products and continual increase in new cases diagnosed each year worldwide. Despite the existence of available effective treatment options in Hemophilia A, there is currently no cure for Hemophilia A. Also, these therapies are expensive and involve lifelong therapy to prevent bleeding.

Segment Analysis

Polaris Market Research has provided the forecasts of the Global Hemophilia A treatment Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are:

  • Market Analysis by Hemophilia A
  • Market Analysis by Treatment Class/Marketed Drugs
  • Market Analysis by G7 countries

SAMPLE TABLE
North America Hemophilia A Treatment Market, By Care Delivery Model, 2016 - 2022 
(USD Million)

North America Hemophilia A Treatment Market, By Care Delivery Model, 2016 - 2022 (USD Million)

 

Key Take-Away